CARDIAC · Injectable
SS-31 + Cardiogen Blend.
Combined cardiac and mitochondrial protection
How it works
Class & mechanism.
Class
Dual Cardiac & Mitochondrial Protection Blend
Mechanism
SS-31 (Elamipretide, D-Arg-dimethylTyr-Lys-Phe-NH2) is an aromatic-cationic tetrapeptide that selectively concentrates in the inner mitochondrial membrane and binds cardiolipin — a phospholipid essential for electron transport chain architecture. By stabilizing cardiolipin-protein interactions, SS-31 preserves cristae structure, enhances ATP synthesis, reduces reactive oxygen species (ROS) production, and blocks opening of the mitochondrial permeability transition pore. Cardiogen (AEDR) complements this by acting upstream at the nuclear level, suppressing p53-driven cardiomyocyte apoptosis and stimulating cardiac progenitor cell regeneration. Together they target cardiac protection at two distinct levels: organelle bioenergetics (SS-31) and gene-regulated cell survival and repair (Cardiogen).
Did you know
SS-31 is so selective for damaged mitochondria that it shows virtually zero benefit in healthy, young hearts — it only activates its repair mechanism when mitochondria are already dysfunctional, making it one of the few compounds that acts as a precision tool rather than a blunt stimulant.
Benefits
What it does.
Dual-layer cardiac protection: SS-31 guards mitochondrial energy production while Cardiogen safeguards cardiac gene expression and cell survival
Reverses age-related cardiac diastolic dysfunction by restoring mitochondrial integrity and reducing proton leak in cardiomyocytes
Reduces oxidative stress at source within mitochondria, limiting downstream inflammation and myocardial fibrosis
Supports post-ischemic cardiac recovery by preserving viable cardiomyocyte mass and reducing pathological remodeling
Improves exercise tolerance and cardiac stroke volume through enhanced ATP availability in heart muscle
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
Late-life SS-31 treatment reversed pre-existing cardiac aging phenotypes including diastolic dysfunction in old mice, reducing mitochondrial ROS production and age-related proton leak in cardiomyocytes — effects absent in young mice with healthy mitochondria, confirming selective action on dysfunctional cells
SOURCE · eLife (2020) — 'Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice'
SS-31 improved cardiac mitochondrial morphology and defective mitophagy in Barth syndrome mouse models (tafazzin knockdown), increasing respiratory chain supercomplex assembly without altering cardiolipin composition — suggesting functional stabilization rather than compositional changes
SOURCE · Scientific Reports (2024) — Russo et al., 'SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in Barth syndrome'
Cardiogen demonstrated stimulation of cardiomyocyte proliferation alongside suppression of fibroblast maturation, reducing scar formation potential; p53 down-regulation confirmed inhibition of apoptosis in myocardial tissue across age groups
SOURCE · St. Petersburg Institute of Bioregulation and Gerontology; Core Peptides research review (2024)
Protocol
How to use it.
Dosing
SS-31 component: 5–20 mg/day subcutaneous injection. Cardiogen component: 5–20 mcg/day subcutaneous injection. Both administered concurrently, typically once daily. Blend formulations vary by compounding pharmacy; confirm individual component concentrations before use.
Cycle
8–12 week treatment cycles, with 4–8 weeks off between cycles. Some protocols use SS-31 continuously for chronic conditions (Barth syndrome trials ran 36 weeks). Cardiogen typically cycled in 10–14 day blocks within the broader SS-31 protocol.
Contraindications
When to skip it.
Injection site reactions are the most common adverse effect for SS-31 (confirmed in clinical trials). Cardiogen has minimal reported adverse effects. Neither compound is FDA-approved for general use. Use with caution alongside cardiac medications — potential additive effects on blood pressure and cardiac function. Not for use in pregnancy. Physician supervision required.
Always cleared with your concierge before protocol start.
Pricing
What it costs.
Indicative range for SS-31 + Cardiogen Blend, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See SS-31 + Cardiogen Blend pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $170–$254 USD